- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01771198
Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
Preliminary Evaluation of SIMVASTATIN as an Alternative Anti-inflammatory Agent in Chronic Rhinosinusitis Refractory to Conventional Medical and Surgical Treatment
Study Overview
Detailed Description
Visit Day 0 (Screening visit):
Once the consent form is signed by the participant identified as eligible, a blood test for the detection of potential biological contraindications to statins will be done the same day called Day 0. It will include a complete blood count, liver function tests (AST, ALT, GGT, bilirubin, ALP), serum CPK and serum electrolytes for renal function (CREAT, urea). For woman who is capable of having children, a serum pregnancy test will be done. The final inclusion of the subject will be confirmed once the biological results obtained and validated.
The patient will be evaluated by Dr. Desrosiers according to clinical and endoscopic criteria. The participant will have to complete two questionnaires: one questionnaire with questions that assess quality of life (SNOT-22), and another questionnaire on nasal and sinus symptoms.
The subject must comply with an observation period of 30 days during which he/she will pursue only washes the salt water.
Visit Day 30 :
Thirty days after the screening visit, only the subjects with normal results of blood tests, are definitely included and will continue the clinical trial. A clinical and endoscopic sinus exam, a serum pregnancy test will be performed again before the administration of the study drug. Bacterial culture sinus using a swab, and brushing of the sinus mucosa under local anesthesia, will also be performed. Brushing sinus will collect the RNA present in epithelial cells and inflammatory nasal mucosa for the identification of markers of inflammation such as IL6, IL8, IL10, TNF. In addition, the participant must complete again the questionnaire on nasal and sinus symptoms and SNOT-22 questionnaire.
The study medication will consist of taking one tablet of 40mg SIMVASTATIN once a day for 30 days. This visit will be seen as the beginning of treatment (Day 30). The subject will also continue with irrigation of sinus with saline for 30 days until the next visit.
Visit Day 60:
This follow-up visit will take place 4 weeks after the beginning of treatment. A clinical and endoscopic sinus exam, blood collections to assess renal and hepatic function, a bacterial sinus culture, and brushing of sinus mucosa will again be performed. The subject must complete again the questionnaire on nasal and sinus symptoms and SNOT-22 questionnaire.
The participant will continue with irrigation of sinus with saline for 30 days until the next visit.
Visit Day 90:
This follow-up visit will take place 8 weeks after the beginning of treatment. A clinical and endoscopic sinus exam will be done again, and the participant must again complete the questionnaire on nasal and sinus symptoms and SNOT-22 questionnaire.
Statistical analysis:
Each participant is his/her own control. At Day 0, Day 30, Day 60 and Day 90, clinical and endoscopic data will be analyzed using the test Brapkar for the qualitative matched observations which is a generalization of the McNemar test for a number of categories greater than 2.
For each gene (IL6, IL8, IL10, TNF), deltaCt values from the analysis of quantitative PCR (Polymerase Chain Reaction) will be compared before and after treatment with SIMVASTATIN using tests for paired samples: a parametric test (t test) or non-parametric test (Wilcoxon Signed-Rank Test).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1T8
- Centre Hospitalier de l'Université de Montréal (CHUM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged between 18 and 65 years.
- Chronic rhinosinusitis with or without nasal polyposis requiring functional endoscopic surgery type of bilateral total ethmoidectomy older than six months
- Failure (clinical and endoscopic score > 1 on a scale of 3) of conventional treatment after surgery followed by local treatment with corticosteroids and saline irrigation)
Exclusion Criteria:
- Cystic Fibrosis
- Primary immunodeficiencies or documented acquired
- Diabetes
- Taking anticoagulants or bleeding disorders
- Taking oral cortisone within 30 days prior to the inclusion
- Taking antibiotics within 30 days prior to the inclusion
- Sinus or nasal surgery in past six months
- Contraindication to statins (pregnancy or lactating; people consuming high quantities of alcohol (3 drinks/day or more), liver disease, severe renal failure, myopathy, hypersensitivity to statins, abnormally elevated transaminase coagulation)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SIMVASTATIN 40mg
SIMVASTATIN tablet of 40mg once a day during 30 days.
Single arm with pre and post treament assessment
|
SIMVASTATIN tablet of 40mg once a day during 30 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sino-Nasal symptomatology
Time Frame: Between Day 30 and Day 60
|
Day 0: Day of recruitment/screening; Day 30: Thirty days after recruitment, day of enrollment of subjects with normal hepatic and renal blood tests, and initiation of SIMVASTATIN 40mg once a day during 30 days; Day 60: Thirty days after Day 30, end of treatment administration; Day 90: Thirty days after Day 60, follow-up visit
|
Between Day 30 and Day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bacterial culture
Time Frame: Between Day 30 and Day 60
|
Between Day 30 and Day 60
|
|
Assessemt of liver and kidney functions
Time Frame: Between Day 0 and Day 60
|
Alterations in hepatic and renal functions will be assessed at screening to exclude indivudals with pre-existing disturbances.
These will be repated at day 60 of treatment to monitor potential treatment-related effects.
|
Between Day 0 and Day 60
|
RNA measurement of inflammatory biomarkers
Time Frame: Between Day 30 and Day 60
|
Total RNA will be extracted from sinus brushing samples.
|
Between Day 30 and Day 60
|
Sinus-Specific Quality of Life (22 questions Sino-nasal outcome test; SNOT-22)
Time Frame: At Day 0 and Day 30 compared to Day 60 and Day 90
|
At Day 0 and Day 30 compared to Day 60 and Day 90
|
|
Aspect of sinus mucosa aspect assessed by sinus endoscopy
Time Frame: At Day 0 and Day 30 compared to Day 60 and Day 90
|
Assessement of the inflammatory aspect of the sinus mucosa by direct endoscopy of the operated sinus cavities.
Grading using the Lund-Kennedy grading system.
|
At Day 0 and Day 30 compared to Day 60 and Day 90
|
Collaborators and Investigators
Investigators
- Principal Investigator: Martin Desrosiers, MD, FRCSC, Centre Hospitalier de l'Université de Montréal (CHUM)
Publications and helpful links
General Publications
- McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004 Mar 1;172(5):2903-8. doi: 10.4049/jimmunol.172.5.2903.
- Lund VJ, Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl. 1995 Oct;167:17-21.
- Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006 Jun;85(6):520-3. doi: 10.1177/154405910608500608.
- Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med. 2011 Mar 1;154(5):293-302. doi: 10.7326/0003-4819-154-5-201103010-00003.
- Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
- Wang W, Le W, Ahuja R, Cho DY, Hwang PH, Upadhyay D. Inhibition of inflammatory mediators: role of statins in airway inflammation. Otolaryngol Head Neck Surg. 2011 Jun;144(6):982-7. doi: 10.1177/0194599811400367. Epub 2011 Apr 5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Sinusitis
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
Other Study ID Numbers
- CE11.288
- Control Number: 156827 (Other Identifier: Health Canada)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinosinusitis
-
Vanderbilt University Medical CenterNeilMed PharmaceuticalsCompleted
-
Boryung Pharmaceutical Co., LtdCompletedChronic Rhinosinusitis | Acute Rhinosinusitis | Recurrent Acute RhinosinusitisKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenUniversity Hospital, Ghent; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaboratorsUnknown
-
Sohag UniversityNot yet recruitingRhinosinusitis Chronic | Rhinosinusitis | Fungal Sinusitis | Rhinosinusitis Acute | Allergic Fungal Rhinosinusitis | Intracranial Extension | Invasive Fungal Sinusitis (Diagnosis)Egypt
-
Unity Health TorontoCompletedChronic RhinosinusitisCanada
-
University of MiamiCompleted
-
Washington University School of MedicineCompletedChronic Rhinosinusitis (Diagnosis) | Allergic Rhinosinusitis | Chronic Eosinophilic RhinosinusitisUnited States
Clinical Trials on SIMVASTATIN
-
University of CopenhagenCompletedCardiovascular Disease | Diabetes MellitusDenmark
-
Organon and CoCompletedMyocardial Infarction | Hypercholesterolemia
-
dr.Frank L.J. VisserenMerck Sharp & Dohme LLCCompletedThe PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study (PANACEA)Metabolic SyndromeNetherlands, Spain
-
University of Sao PauloCompletedCoronary Heart Disease
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCCompletedMetabolic SyndromeUnited States
-
Peking Union Medical College HospitalUnknownAtherosclerosisChina
-
Organon and CoCompletedHypercholesterolemia
-
Hue University of Medicine and PharmacyUniversità degli Studi di SassariUnknownChronic Kidney Diseases | HypercholesterolemiaVietnam
-
Federal State Budgetary Scientific Institution,...Completed
-
Organon and CoCompleted